Complex Regulatory Pathways Pose Hurdles For Effective CLs; Cipla’s Hamied Calls For Automatic Licensing Rights
This article was originally published in PharmAsia News
Cipla Chairman Yusuf Hamied has proposed an automatic licensing mechanism that could avoid the need for a compulsory license and would allow generic firms to launch patented drugs via an automatic route.
You may also be interested in...
MUMBAI - Known for supplying low-priced anti-retroviral cocktail therapy to frontline African nations to combat the spread of HIV/AIDS, Cipla - India's largest drug maker by market share - is in discussions with U.S. health agencies to boost production of antiviral oseltamivir, the generic for Roche's Tamiflu for treating the rapidly spreading H1N1 virus
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.